Massive hope for pancreatic cancer pill after trial saw tumours vanish

Cancer became undetectable on scans in one in 12 of the patients given daraxonrasib along with chemotherapy in early medical trials.

Daraxonrasib.jpeg
RASONQUE (AKA Daraxonrasib) by Revolution Medicines (Redwood City, California)



Daraxonrasib (RASONQUE™) FDA Approved: How It Targets RAS in Pancreatic Cancer | MOA

Daraxonrasib1.png
Daraxonrasib2.png

This is the key hero guy:
Image of Gregory Verdine, Ph.D.

Gregory Verdine is a pioneer in the field of chemical biology, a serial biotech entrepreneur and a life science venture capitalist. In an independent academic career at Harvard University and Harvard Medical School spanning nearly 3 decades, he has elucidated the molecular mechanism of epigenetic DNA methylation and the pathways by which certain genotoxic forms of DNA damage are surveilled in and eradicated from the genome. He is a leading figure in the field of new therapeutic modalities, and has developed a new class of therapeutics termed stapled peptides, which are currently in clinical development and have received much attention for their ability to drug targets previously considered “undruggable.” Dr. Verdine is Erving Professor of Chemistry in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology.
 
Last edited:
Surely this has to be usable against other cancers beyond just pancreatic, anything RAS mutation driven essentially? Could be massive.
 

Users who are viewing this thread

Pakistan Defence Latest

Country Watch Latest

Back
Top